Here’s what you should know:
1. After Valeant repays the debt next week, the company will have reduced its debt by more than $6.7 billion since the end of the first quarter of 2016.
2. Valeant still has approximately $25.5 billion in debt.
3. CEO Joseph Papa said, “We are able to further reduce our debt due to strong operational cash flow. Though we remain focused on reducing debt, we are also continuing to invest in our core businesses where we can both drive growth and make an impact on patients globally.”
4. Valeant’s shares opened at $19.62 on Jan. 26, they peaked at $20.17 at 10 a.m. EST and were trading at $19.38 as of 1 p.m. EST.
More articles on supply chain:
McKesson to close New Jersey distribution center, lay off 102 employees — 3 insights
Goldman Sachs a ‘sell’ on Valeant — 3 insights
Congress suspends medical device tax through stopgap spending deal — 6 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.